Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • M&A

Quidel Announces Stockholder Approval Of Ortho Acquisition And Business Combination

By Benzinga Newsdesk
Today, 10:10 PM
Quidel Corporation (NASDAQ:QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the previously announced acquisition of Ortho Clinical Diagnostics Holdings plc (“Ortho”) by Quidel and

OCDX

Read More
27 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For May 4, 2022

By Benzinga Insights
Today, 10:10 PM
  Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

ABC

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Upgrades

Evercore ISI Group Upgrades Ortho Clinical Diagnostic to Outperform, Announces $21 Price Target

By Benzinga Newsdesk
Today, 10:10 PM
Evercore ISI Group analyst Vijay Kumar upgrades Ortho Clinical Diagnostic (NASDAQ:OCDX) from In-Line to Outperform and announces $21 price target.

OCDX

Read More
1 minute read
  • Earnings

Ortho Clinical Diagnostic: Q4 Earnings Insights

By Benzinga Insights
Today, 10:10 PM
Ortho Clinical Diagnostic (NASDAQ:OCDX) reported its Q4 earnings results on Wednesday, February 16, 2022 at 04:30 PM. Here's what investors need to know about the announcement.

OCDX

Read More
10 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For February 16, 2022

By Benzinga Insights
Today, 10:10 PM
  Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million.

ACVA

Read More
2 minute read
  • Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights
Today, 10:10 PM
Gainers Quidel (NASDAQ:QDEL) shares increased by 7.4% to $106.2 during Friday's after-market session. The market value of their outstanding shares is at $4.4 billion.

ARDS

Read More
2 minute read
  • Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights
Today, 10:10 PM
Gainers Cidara Therapeutics (NASDAQ:CDTX) stock moved upwards by 14.1% to $0.91 during Thursday's after-market session. The company's market cap stands at $60.6 million.

ARDS

Read More
1 minute read
  • FDA
  • News

Wholly-owned Subsidiary Shanghai Medconn Biotechnology And Ortho Biotechnology Development Entered into Strategic Cooperation And Joint Venture Agreement

By Benzinga Newsdesk
Today, 10:10 PM
https://ir.orthoclinicaldiagnostics.com/news-releases/news-release-details/wholly-owned-subsidiary-shanghai-medconn-biotechnology-co-ltd

OCDX

Read More
1 minute read
  • Analyst Ratings
  • Pre-Market Outlook
  • Price Target
  • Small Cap

10 Biggest Price Target Changes For Monday

By Lisa Levin
Today, 10:10 PM
Morgan Stanley cut Foot Locker, Inc. (NYSE: FL) price target from $66 to $47. Foot Locker shares fell 0.1% to $41.90 in pre-market trading.

CVNA

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News
  • Price Target

HC Wainwright & Co. Downgrades Ortho Clinical Diagnostic to Neutral, Announces $24.68 Price Target

By Benzinga Newsdesk
Today, 10:10 PM
HC Wainwright & Co. analyst Yi Chen downgrades Ortho Clinical Diagnostic (NASDAQ:OCDX) from Buy to Neutral and announces $24.68 price target.

OCDX

Posts navigation

1 2 3 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service